C91.12 Chronic lymphocytic leukemia of B-cell type in relapse

Name of the Condition

• Chronic lymphocytic leukemia of B-cell type in relapse
• ICD-10 Code: C91.12

Summary

Chronic lymphocytic leukemia of B-cell type in relapse (C91.12) is a subtype of chronic lymphocytic leukemia (CLL) where the disease reappears after a period of remission. It involves the recurrence of abnormal B lymphocytes in the blood, bone marrow, or lymphoid tissues, indicating renewed disease activity. This condition is characterized by the return of detectable cancer cells or symptoms following a prior response to treatment, requiring reevaluation and potential adjustment of therapy.

Causes

The exact cause of CLL, including relapse, is not fully understood. It involves genetic mutations in B lymphocytes that disrupt normal cell regulation, leading to uncontrolled proliferation. Contributing factors may include environmental exposures, genetic predispositions, and alterations in immune system function. Relapse typically occurs due to residual disease cells that survived initial treatment or developed resistance, though the underlying genetic mutations may persist even after remission.

Risk Factors

• Increasing age (most common in adults over 60)
• Family history of CLL or other lymphoid cancers
• Certain genetic conditions (e.g., inherited immune disorders)
• Prior exposure to certain chemicals or radiation (less clearly established)
• Previous treatment response (relevant to relapse risk)

Symptoms

• Fatigue and weakness
• Swollen lymph nodes (especially in the neck, armpits, or groin)
• Enlarged spleen or liver
• Frequent infections due to impaired immune function
• Unexplained weight loss
• Night sweats or fever

Diagnosis

Diagnosis of relapsed CLL involves clinical evaluation and laboratory testing. Blood tests may show elevated lymphocyte counts or abnormal cell morphology. Bone marrow biopsy can confirm the presence of abnormal B cells. Imaging studies (e.g., CT scans) may assess lymph node or organ involvement. Molecular testing for genetic markers (e.g., IGHV mutation status, TP53 mutations) helps guide treatment decisions. Documentation of prior remission and treatment history is critical for confirming relapse.

Treatment Options

Treatment for relapsed CLL depends on prior therapies, disease biology, and patient factors. Options may include targeted therapies (e.g., BTK inhibitors, BCL-2 inhibitors), immunotherapy (e.g., monoclonal antibodies), or chemotherapy. Clinical trials may be considered for eligible patients. Treatment goals focus on disease control, symptom relief, and extending remission duration. Regular monitoring is essential to assess response and adjust therapy as needed.

Prognosis and Follow-Up

Prognosis for relapsed CLL varies based on disease characteristics and treatment response. Some patients achieve long-term remission with effective therapy, while others may experience progressive disease. Follow-up includes regular blood tests, imaging, and clinical assessments to detect further relapse or complications. Ongoing monitoring helps guide timely intervention and supports personalized care planning.

Complications

Complications of relapsed CLL may include severe infections due to immune dysfunction, anemia or thrombocytopenia from bone marrow infiltration, transformation to a more aggressive lymphoma (Richter's transformation), and organ damage from enlarged lymph nodes or spleen. Treatment-related side effects (e.g., cytopenias, infections) may also occur, requiring careful management.

Lifestyle & Prevention

While CLL cannot be prevented, lifestyle measures may support overall health. Maintaining a balanced diet, regular exercise, and adequate rest can help manage symptoms. Avoiding exposure to infections (e.g., vaccinations, hygiene practices) is important due to immune suppression. Patients should avoid tobacco and limit alcohol, as these may worsen health outcomes. Stress management and regular medical check-ups are also recommended.

When to Seek Professional Help

Seek medical attention if new or worsening symptoms occur, such as persistent fatigue, unexplained weight loss, fever, or swollen lymph nodes. Prompt evaluation is necessary if signs of infection (e.g., fever, chills) or bleeding (e.g., bruising, bleeding gums) develop. Patients should also contact their healthcare provider if treatment side effects become severe or unmanageable.

Tips for Medical Coders

Document the diagnosis of relapsed CLL with specificity, including clinical evidence of disease recurrence (e.g., lab results, imaging) and prior remission status. Ensure documentation supports the use of C91.12 by confirming the relapse phase and excluding other CLL subtypes. Verify that treatment history and response to prior therapy are clearly recorded, as these factors influence coding accuracy. Follow clinical guidelines for distinguishing relapse from progressive disease to ensure appropriate code assignment.